Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns Overweight Rating from Cantor Fitzgerald

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They presently have a $50.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 38.73% from the stock’s previous close. CRNX […]

Related Keywords

Dana Pizzuti ,Stephenf Betz ,Cantor Fitzgerald ,Morgan Stanley ,Nasdaq ,Jefferies Financial Group ,Crinetics Pharmaceuticals Price Performance ,Mirae Asset Global Investments Co ,Jennison Associates ,Crinetics Pharmaceuticals ,News Ratings For Crinetics Pharmaceuticals Daily ,Crinetics Pharmaceuticals Company Profile ,Wealth Partners ,Jpmorgan Chase Co ,Analyst Recommendations For Crinetics Pharmaceuticals ,Crinetics Pharmaceuticals Inc ,Get Free Report ,Financial Group ,Mirae Asset Global Investments ,Asset Global Investments ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Reiterated Rating ,